title: Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis.
abstract: The rapidity and efficacy of a short course of liposomal amphotericin B was evaluated in 29 children affected by visceral leishmaniasis (Leishmania infantum). Their overall health status was assessed using the prognostic inflammatory and nutritional index (PINI), and their haematological status by the reticulocyte count and haemoglobin blood levels. All these quantities were measured on day 0, and 3 and 10 d after starting therapy. A significant decrease of inflammatory signs, associated with an improved reticulocyte count, was recorded after 3 d of therapy. A significant increase of haemoglobin levels was also observed 10 d after the start of treatment. The early reduction of inflammatory signs and the improvement of bone marrow function in most patients confirmed the validity of amphotericin B therapy. The PINI score is helpful in assessing the severity of visceral leishmaniasis and the follow-up of its treatment.
authors: Department of Infectious Diseases, Gaslini Children's Hospital, Genoa, Italy.
authors: E
authors: E
authors: Castagnola
authors: R N
authors: RN
authors: Davidson
authors: P
authors: P
authors: Fiore
authors: L
authors: L
authors: Tasso
authors: G
authors: G
authors: Rossi
authors: S
authors: S
authors: Mangraviti
authors: L
authors: L
authors: Di Martino
authors: S
authors: S
authors: Scotti
authors: A
authors: A
authors: Cascio
authors: R
authors: R
authors: Pempinello
authors: L
authors: L
authors: Gradoni
authors: R
authors: R
authors: Giacchino
mesh_terms: D000293:Adolescent; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000740:Anemia / Q000150:complications / Q000188:drug therapy; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004337:Drug Carriers; D005260:Female; D006801:Humans; D007223:Infant; D007558:Italy; D018314:Leishmania infantum; D007898:Leishmaniasis, Visceral / Q000150:complications / Q000188:drug therapy*; D008081:Liposomes; D008297:Male; D012720:Severity of Illness Index
chemical_list: D000981:Antiprotozoal Agents; D004337:Drug Carriers; D008081:Liposomes; C068538:liposomal amphotericin B; D000666:Amphotericin B